Erasca Jumps on Merck Collaboration for RAS-Mutant Cancer Combo Trial
Erasca rises after teaming with Merck to test ERAS-0015 + Keytruda in RAS cancers, showing early tumor shrink but past safety concern.
/ 181 items
#XY Event-Driven Stocks↓
MoonLake Gets Major Analyst Boost After “Best-in-Class” FDA Meeting
MoonLake gets FDA support for its HS drug, showing top results. Analysts stay bullish with strong growth potential ahead.
Atara Biotherapeutics Stock Soars After FDA Green Light for Cancer Therapy
Atara stock jumps 52% after FDA signals its cancer therapy may get approved, boosting hope for patients and investors.
Angelini Pharma Buys US Catalyst for $4.1 Billion in State-Backed Deal
Angelini is set to buy US-based Catalyst for $31.50 per share in a state-backed deal, expanding into rare neurological diseases and entering the US market.
Dystrophin Miss Sends Entrada Shares Tumbling Despite Functional Win
Entrada DMD drug was safe and helped movement a bit, but low muscle protein results disappointed investors, stock -60%.
enGene Stock Crashes After Bladder Cancer Drug Shows Solid Safety but Disappointing Durability
enGene bladder cancer drug shows good safety and early response, but weak long-term results; stock drops ~66% after update.